加载中
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
收盘时
US$1.04
−US$0.10 · -8.77%
盘后
US$1.04
US$0.00 · 0.00%
10月13日 16:04 ET
盘中时间采用ET。市场数据可能有所延迟。
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
日内区间
当前US$1.04
52周区间
当前US$1.04
盘中时间采用ET。市场数据可能有所延迟。
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
日内区间
当前US$1.04
52周区间
当前US$1.04
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.92亿 USD | 1.97亿 USD | 1.85亿 USD | 1.65亿 USD | 1.39亿 USD |
| 销货成本 | 5485.8万 USD | 5813万 USD | 5787.7万 USD | 5457.5万 USD | 4881.7万 USD |
| 毛利 | 1.37亿 USD | 1.39亿 USD | 1.27亿 USD | 1.1亿 USD | 9057.9万 USD |
| 销售、一般及管理费用 | 1.02亿 USD | 1.07亿 USD | 9882.6万 USD | 1.71亿 USD | 5396.2万 USD |
| 营业费用 | 1.02亿 USD | 1.07亿 USD | 9882.6万 USD | 1.71亿 USD | 5601.8万 USD |
| 利息支出 | 1096.1万 USD | 1100.1万 USD | 636.3万 USD | 404.7万 USD | 167.3万 USD |
| 折旧和摊销 | 367万 USD | 357.4万 USD | 299.4万 USD | 219.9万 USD | 140万 USD |
| 营业利润 | 3555.1万 USD | 3161.1万 USD | 2865.7万 USD | −6072.2万 USD | 3456.1万 USD |
| 净利润 | 2704.5万 USD | 315.7万 USD | 331.6万 USD | −96.9万 USD | 3261.9万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
上涨空间 284.62%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI136.07万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF40.78万0.00%954亿 USD0.05%US$232.54-0.42%
Dimensional - US Small Cap ETFDFAS25.77万0.00%338.04亿 USD0.31%US$78.33+0.20%
U.S. Micro Cap Portfolio ETFDFMC14.3万0.00%75.44亿 USD0.43%US$57.78+0.14%
iShares Micro-Cap ETFIWC9.59万0.01%13.17亿 USD0.60%US$179.6-1.13%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4万0.03%1.16亿 USD0.73%US$15.6501-1.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
